Current Report Filing (8-k)
02 July 2019 - 6:50AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
_________________
FORM
8-K
_________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
June
30, 2019
Date
of Report (date of earliest event reported)
_________________
OpGen,
Inc.
(Exact
name of Registrant as specified in its charter)
_________________
Delaware
(State
or other jurisdiction of incorporation or organization)
|
|
001-37367
(Commission
File
Number)
|
|
06-1614015
(I.R.S.
Employer
Identification Number)
|
708
Quince Orchard Road, Suite 205
Gaithersburg, MD 20878
(Address of principal executive offices, including zip code)
(240)
813-1260
(Registrant’s telephone number, including area code)
Not
Applicable
(Former name or former address, if changed since last report)
_________________
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[_] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock
|
OPGN
|
The
Nasdaq Capital Market
|
Common
Stock Warrants (IPO)
|
OPGNW
|
The
Nasdaq Capital Market
|
|
Item
5.02
|
Departure
of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On
June 28, 2019, David M. Rubin, Ph.D., a director of OpGen, Inc. (the Company”) since 2015 submitted his resignation as a
director effective June 30, 2019. In addition, Timothy J.R. Harris, Ph.D., D.Sc., a director of the Company since 2015, who had
previously notified the Chairman of the Board of Directors of the Company that, for personal reasons, he would not seek to be
re-nominated for election at the next annual meeting of the Company, notified the Company that his service would end on June 30,
2019. There was no disagreement between either of Dr. Rubin or Dr. Harris and the Company leading to the decisions to resign.
Dr.
Rubin had served on the Audit Committee of the Board. The Board re-appointed Tina S. Nova, Ph.D. to the Audit
Committee effective July 1, 2019. The Board determined that Dr. Nova is independent and has the necessary skills and
qualifications to serve on the Audit Committee.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
OpGen, Inc.
|
|
|
By:
|
|
/s/
Timothy C. Dec
|
|
|
Name:
|
|
Timothy C. Dec
|
|
|
Title:
|
|
Chief Financial
Officer
|
Date:
July 1, 2019
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2023 to Aug 2024